The company's customer-centric innovation starts with deeply understanding a client's operational issues and end-consumer needs. They then reframe these commercial challenges as specific biological problems that their R&D can measure, target, and solve.
The company's CSO emphasizes that deep customer knowledge allows them to innovate beyond client requests. Instead of just incremental improvements ('a faster horse'), they aim to develop transformative solutions that customers might not even know are possible ('a car').
Industrial biotech startups often fail trying to scale cost-effectively. Since customers rarely pay a premium for sustainability alone, directly replacing a cheap petrochemical is a losing battle. A better strategy is to develop unique products with novel functionalities.
Despite serving cost-sensitive sectors like agriculture, Novonesis maintains pharma-like profit margins. They achieve this by charging based on the demonstrable value their products create, such as measurable weight gain in livestock or increased output in biofuel plants.
Despite being in many consumer products, Novonesis avoids co-branding. They empower their customers' billion-dollar brands (e.g., P&G, Unilever) rather than building their own consumer recognition, which could complicate B2B relationships.
The merger of Novozymes and Chr. Hansen wasn't a typical cost-synergy play. They maintained their combined R&D spending ratio to proliferate their pipeline, using complementary technologies to solve problems neither company could address alone.
Beyond boosting productivity, Novonesis employs genetic engineering as a safety tool. They modify production strains to remove any latent ability to become harmful, ensuring products for food and feed are exceptionally clean and safe, a key advantage over using wild-type strains.
The company invested heavily in enzymes for converting waste biomass to fuel, only to realize the project was failing because of logistics—collecting and pre-treating waste—which were outside their control. This serves as a cautionary tale for dosing R&D when success hinges on external factors.
Long before the AI boom, Novonesis began creating structured data repositories in the 2000s to manage high-throughput screening data. This decades-long data discipline is now a massive competitive advantage, providing the clean foundation necessary for effective machine learning and digital twins.
The company once invested 13% of revenue in R&D but saw stagnant growth. The issue was that new products were primarily replacing older ones, not creating new markets. This improved profitability but highlighted the need to balance R&D between incremental improvements and true market expansion.
Novonesis has shifted enzyme discovery from the lab to computers. Using AI tools like AlphaFold, they predict protein structures and identify new enzyme families based on structural motifs rather than sequence similarity. This allows them to find novel functionalities much faster than traditional methods.